Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

401-420 of 991 trials

Hyperkalaemia in Children: SZC Treatment Study

We are studying whether the medication SZC can safely normalize potassium levels in children with hyperkalaemia. The trial will also check how well it maintains these levels over time.

High Potassium Levels (Hyperkalemia)6-12 monthsConfirmation phase (III)16-20 visits No Placebo Investigational Medicines Cost ReimbursementNephrologyPediatrics

Neutropenia: Mavorixafor Study

We are investigating a new medication, mavorixafor, for people with neutropenia who have frequent infections. The study will assess how well it works and its safety compared to a placebo.

Neutropenia1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInfectious DiseasesInternal Medicine

Advanced Epithelial Ovarian Cancer: Radspherin® Treatment

We are studying whether Radspherin® can improve survival and quality of life for patients with advanced ovarian cancer and peritoneal metastasis. This trial focuses on those scheduled for chemotherapy and surgery.

Peritoneal Carcinomatosis>2 yearsEfficacy phase (II)≤5 visits Standard Medicines Cost Reimbursement Partially RemoteGynecology and ObstetricsOncology

Systemic Lupus Erythematosus: Ianalumab Study

We are evaluating a new medication, ianalumab, for patients with systemic lupus erythematosus to see if it helps improve symptoms and reduce flare-ups compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementRheumatology

Seasonal Allergic Rhinitis: PQ Grass Treatment for Kids

We are studying a new treatment for children and teens with seasonal allergic rhinitis caused by grass pollen. The goal is to see if it helps reduce symptoms and is safe for long-term use.

Allergic Rhinitis and Conjunctivitis>2 yearsConfirmation phase (III)>20 visits Standard Medicines Cost Reimbursement Partially RemoteAllergologyPediatrics

PIK3CA-Related Overgrowth Spectrum: Alpelisib Study

We are investigating whether the medication alpelisib is safe and effective for individuals with PIK3CA-related overgrowth spectrum. This study includes both children and adults to assess its impact on their symptoms and overall health.

PIK3CA-Related Overgrowth Spectrum6-12 monthsEfficacy phase (II)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal MedicineOncology

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Preventing Blood Clots: REGN9933 and REGN7508 Study

We are studying two new medications to see if they can help prevent blood clots in adults with a peripherally inserted central catheter. The trial will also assess how safe these treatments are.

Venous Thromboembolism3-6 monthsEfficacy phase (II)6-10 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyHematology

Head and Neck Cancer: Dostarlimab Treatment Study

We are studying whether dostarlimab can improve outcomes for adults with locally advanced head and neck cancer after initial treatment. Participants will receive either the new treatment or a placebo to compare effects.

Squamous Cell Carcinoma of the Head and Neck3-6 monthsConfirmation phase (III)11-15 visits Investigational Medicines Cost ReimbursementOncology

Crohn's Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn's disease. The study aims to see if it helps reduce symptoms and achieve remission compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

Primary IgA Nephropathy: Long-Term Study of Iptacopan

We are evaluating the long-term safety and tolerability of iptacopan in adults with primary IgA nephropathy. This study follows participants who have completed an earlier trial to see how well the treatment works over time.

IgA Nephropathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNephrology

Thyroid Eye Disease: Lu AG22515 Treatment

We are investigating the effects of Lu AG22515 on eye bulging in adults with moderate-to-severe Thyroid Eye Disease. This study aims to see if it can improve symptoms related to this condition.

Thyroid Eye Disease1-2 yearsSafety phase (I)16-20 visits No Placebo Investigational Medicines Cost ReimbursementEndocrinologyOphthalmology

Frontotemporal Dementia: DNL593 Study

We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.

Frontotemporal Dementia1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Chronic Rhinosinusitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsConfirmation phase (III)Standard Medicines Cost Reimbursement Partially RemoteOtolaryngologyPulmonology

Heart Failure: Stopping Beta-Blockers

We are studying whether discontinuing beta-blockers is as safe for patients with improved heart function as continuing the medication. This trial aims to understand the effects on heart failure relapse and overall heart health.

Heart Failure>2 yearsConfirmation phase (III)Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Ulcerative Colitis and Crohn’s Disease: Vedolizumab for Kids

We are studying the long-term safety of vedolizumab in children with ulcerative colitis or Crohn’s disease. The trial also looks at how this treatment affects their quality of life and related health events.

Ulcerative ColitisCrohn's Disease1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Refractory Focal Onset Epilepsy: BHV-7000 Study

We are testing a new medication, BHV-7000, to see if it can help reduce seizures in adults with refractory focal onset epilepsy. The study compares its effects to a placebo to evaluate safety and effectiveness.

Focal Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

BHV-7000 for Idiopathic Generalized Epilepsy

We are studying a new treatment for people with idiopathic generalized epilepsy who have generalized tonic-clonic seizures. The trial will compare its effects to a placebo to see if it helps reduce seizure frequency and is safe to use.

Idiopathic Generalized Epilepsy6-12 monthsEfficacy phase (II)Confirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Refractory Focal Onset Epilepsy: BHV-7000 Safety Study

We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.

Focal Epilepsy1-2 yearsEfficacy phase (II)6-10 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurology

Perennial Allergic Rhinitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, to see if it helps adults with perennial allergic rhinitis experience fewer nasal symptoms. This study compares its effects to a placebo treatment.

Perennial Allergic RhinitisConfirmation phase (III)6-10 visits Standard Medicines Cost Reimbursement Partially RemoteAllergologyOtolaryngologyPulmonology

Search Clinical Trials in the European Union